Xiamen Humanity Hospital
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
China treats chordoma through aggressive surgery and advanced particle radiation therapy within specialized multidisciplinary centers. Surgeons prioritize wide en bloc resection for spinal cases or endoscopic transnasal surgery for skull-base tumors. Treatment plans often combine high-precision carbon ion or proton beams to eliminate remaining microscopic disease.
Bookimed Expert Insight: Xiamen Humanity Hospital stands out for its massive scale, serving nearly 1,000,000 patients annually. This high volume across 47 departments allows for rapid multidisciplinary collaboration. Professor Liu Shi Xin at this facility holds high-level certifications in radiation oncology. His expertise in VMAT and SBRT is vital for chordoma patients who cannot access carbon ion centers.
Patient Consensus: Patients note that successful outcomes depend on surgeons achieving full removal without nerve damage. They frequently emphasize that coordinated planning between surgical and radiation teams is more important than the operation alone.
Chordoma treatment in China involves surgical risks like nerve injury, hemorrhage, and anesthesia reactions. Post-operative hurdles include cerebrospinal fluid leaks, wound infections, and blood clots. Long-term impacts may include permanent nerve deficits, chronic neuropathic pain, and bowel or bladder dysfunction depending on tumor location.
Bookimed Expert Insight: China's large-scale hospitals like Xiamen Humanity Hospital manage around 1,000,000 patients every year. This massive clinical volume allows surgeons there to see rare chordoma cases more frequently than many Western centers. When choosing a facility, look for those with JCI accreditation and specialized neuro-oncology teams to ensure safety protocols match international standards despite the high patient turnover.
Patient Consensus: Patients note that regaining basic functions like walking or swallowing takes much longer than expected. Many emphasize that long-term physical therapy and bowel retraining are necessary parts of the recovery journey.
Proton Beam Therapy (PBT) uses light particles with low-energy transfer to minimize toxicity. Carbon Ion Radiotherapy (CIRT) employs heavy particles to destroy radioresistant chordoma cells. While both utilize the Bragg peak for precision, CIRT offers higher biological effectiveness and destroys oxygen-deprived tumor zones.
Bookimed Expert Insight: While machine type is important, clinical leadership in China is a key quality signal. Dr. Liu Shi Xin at Xiamen Humanity Hospital serves as Vice Chairman of the Particle Therapy Professional Committee. This institutional expertise is crucial for chordoma, as specialized centers can manage over 1,000,000 annual patient visits while maintaining JCI standards.
Patient Consensus: Patients note that while CIRT hits harder against resistant tumors, PBT is primarily valued for sparing healthy tissue near the spine. Success often depends on having a skilled surgical resection before starting any particle therapy.
Shanghai and Guangzhou serve as Chinas primary hubs for chordoma treatment within Tier-1 cities. These centers integrate medical particle accelerators with multidisciplinary teams specializing in skull base and sacral tumors. Shanghai specifically provides unique access to both proton and carbon ion radiotherapy for radioresistant bone malignancies.
Bookimed Expert Insight: While machine access is critical, specialized leadership often dictates outcomes. Dr. Liu Shi Xin at Xiamen Humanity Hospital is a leading figure in the Chinese Anti-Cancer Association particle therapy committee. This connection ensures patients receive treatment at a facility where the infrastructure is matched by national-level expertise in precise radiation protocols.
Patient Consensus: Patients emphasize finding a center that coordinates surgery and specialized radiation under one roof. They note that the first surgery is critical and prefer teams with high chordoma-specific volume.
China offers unique advantages for chordoma treatment due to its role as a global leader in carbon ion radiotherapy. This rare modality is essential for destroying radioresistant tumor cells near the spine. Patients benefit from exceptionally high surgical volumes and streamlined paths to specialized multidisciplinary care.
Bookimed Expert Insight: While many countries have specialized oncology centers, China stands out for institutional scale. Xiamen Humanity Hospital alone serves 1,000,000 patients annually. At Fuda Cancer Hospital, specialists have treated 30,000+ international patients from over 100 countries. This massive volume means multidisciplinary teams handle rare cases like chordoma daily. Professor Liu Shi Xin at Xiamen Humanity Hospital holds leadership roles in national particle therapy committees. This level of specialization often leads to more refined planning for tumors near critical structures.
Patient Consensus: Patients value the speed of access and lower costs compared to Western centers. They emphasize choosing specific surgeons with high-volume experience rather than just a hospital.
Outpatient treatment timelines for proton or carbon ion therapy in China typically span 1 to 6 weeks. Carbon ion therapy often concludes within 1 to 4 weeks due to higher biological impact. Standard proton therapy for chordoma usually requires 5 daily sessions per week for 4 to 8 weeks.
Bookimed Expert Insight: While carbon ion therapy offers shorter schedules, chordoma treatment often requires the full 6–8 week proton protocol for skull-base precision. Hospitals like Xiamen Humanity Hospital manage massive volumes of 1,000,000 annual patients. This scale ensures high-level expertise in complex radiation oncology. Professor Liu Shi Xin at Xiamen is a national leader in particle therapy committees. His leadership indicates that Chinese centers prioritize rigorous academic oversight for these advanced technologies.
Patient Consensus: Patients note the treatment feels more like a daily job than a medical procedure. The main challenge is the daily repetition and staying in nearby housing rather than the short beam time.